Gilead Sciences (GILD) Capital Expenditures (2009 - 2026)
Gilead Sciences' (GILD) quarterly Capital Expenditures came in at $117.0 million in Q1 2026, up 12.5% YoY from $104.0 million in Q1 2025, and down 42.93% on a QoQ basis from $205.0 million in Q4 2025.
Gilead Sciences (GILD) Capital Expenditures (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Capital Expenditures data on file, last reported at $117.0 million in Q1 2026.
- Quarterly Capital Expenditures rose 12.5% year-over-year to $117.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $576.0 million (up 10.34% YoY) and the FY2025 annual result came in at $563.0 million, up 7.65% from the prior year.
- Capital Expenditures declined to $117.0 million in Q1 2026, from $205.0 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $247.0 million in Q1 2022 to a low of $104.0 million in Q1 2025.
- A 5-year average of $148.0 million and a median of $141.0 million in 2024 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures soared 49.7% — and 2023, when it tumbled 55.87%.
- Tracing GILD's Capital Expenditures over 5 years: stood at $181.0 million in 2022, then increased by 18.78% to $215.0 million in 2023, then tumbled by 31.63% to $147.0 million in 2024, then soared by 39.46% to $205.0 million in 2025, then tumbled by 42.93% to $117.0 million in 2026.
- The last three Capital Expenditures figures came in at $117.0 million (Q1 2026), $205.0 million (Q4 2025), and $147.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.51 Bn | 632.75 Bn | 17.26 Bn | 1.32 Bn |
| 2 | AbbVie | 470.67 Bn | 464.10 Bn | 12.70 Bn | 322.00 Mn |
| 3 | Merck | 378.00 Bn | 370.86 Bn | 12.21 Bn | 893.00 Mn |
| 4 | Novartis Ag | 303.24 Bn | 295.55 Bn | 11.24 Bn | 321.00 Mn |
| 5 | Astrazeneca | 257.85 Bn | 252.95 Bn | 12.86 Bn | 1.86 Bn |
| 6 | Amgen | 236.64 Bn | 222.65 Bn | 7.24 Bn | 513.00 Mn |
| 7 | Gilead Sciences | 182.27 Bn | 179.09 Bn | 6.22 Bn | 140.00 Mn |
| 8 | Pfizer | 159.46 Bn | 147.76 Bn | 10.94 Bn | 533.00 Mn |
| 9 | Gsk | 106.20 Bn | 102.03 Bn | 8.24 Bn | -440.07 Mn |
| 10 | Sanofi | 55.06 Bn | 47.68 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 140.00 Mn |
| Jun 30, 2026 | 140.00 Mn |
| Mar 31, 2026 | 117.00 Mn |
| Mar 31, 2026 | 117.00 Mn |
| Dec 31, 2025 | 205.00 Mn |
| Dec 31, 2025 | 205.00 Mn |
| Sep 30, 2025 | 147.00 Mn |
| Sep 30, 2025 | 147.00 Mn |
| Jun 30, 2025 | 107.00 Mn |
| Jun 30, 2025 | 107.00 Mn |
| Mar 31, 2025 | 104.00 Mn |
| Mar 31, 2025 | 104.00 Mn |
| Dec 31, 2024 | 147.00 Mn |
| Dec 31, 2024 | 147.00 Mn |
| Sep 30, 2024 | 141.00 Mn |
| Sep 30, 2024 | 141.00 Mn |
| Jun 30, 2024 | 130.00 Mn |
| Jun 30, 2024 | 130.00 Mn |
| Mar 31, 2024 | 105.00 Mn |
| Mar 31, 2024 | 105.00 Mn |